Editorial
Copyright ©The Author(s) 2024.
World J Gastroenterol. Apr 7, 2024; 30(13): 1780-1790
Published online Apr 7, 2024. doi: 10.3748/wjg.v30.i13.1780
Table 1 Recruiting colorectal cancer clinical trials that include paclitaxel
Clinical trial number
Treatment
Stage
Country
NCT05185947Paclitaxel + nilotinibPhase IIUnited States
NCT04731467Nivolumab, Nab-paclitaxel, gemcitabinePhase I/IIUnited States, Spain
NCT03129139Minnelide™ + protein-bound paclitaxelPhase IUnited States
NCT05453825Navicixizumab + paclitaxel or irinotecanPhase IIUnited States
NCT05107674NX-1607 (+ paclitaxel)Phase Ia/bUnited States, United Kingdom
NCT036788839-ING-41, gemcitabine, doxorubicin, carboplatin, Nab-paclitaxel, paclitaxel, irinotecanPhase IIUnited States, Belgium, Canada, France, Netherlands, Portugal, Spain
NCT05395910PaclitaxelPhase ISingapore (note: Peritoneal carcinomatosis)
NCT04666688LYT-200, tislelizumab, gemcitabine + Nab-paclitaxelPhase I/IIUnited States
NCT04444921Carboplatin, nivolumab, paclitaxelPhase IIIUnited States (note: Anal cancer)
NCT04083599GEN1042, pembrolizumab, cisplatin, carboplatin, 5-FU, gemcitabine, Nab-paclitaxel, pemetrexed, paclitaxelPhase I/IIUnited States, Denmark, France, Georgia, Germany, Israel, Italy, Republic of Korea, Republic of Moldova, Spain, Taiwan, United Kingdom
NCT03872947TRK-950, irinotecan, leucovorin, 5-FU, gemcitabine, cisplatin, carboplatin, ramucirumab, paclitaxel, nivlumab, pembrolizumab, imiquimod cream, bevacizumab, topotecan, PCDPhase IUnited States, France
NCT04644068ADZ5305, paclitaxel, carboplatin, T-Dxd, Dato-DXd, camizestrantPhase I/IIUnited States, Australia, Canada, China, Czechia, Hungary, Italy, Japan, Republic of Korea, Poland, Russian Federation, Spain, United Kingdom
NCT06047379NEO212, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, FOLFIRI, bevacizumabPhase I/IIUnited States
Table 2 Recruiting docetaxel study in colorectal cancer
Clinical trial number
Treatment
Stage
Country
NCT04553692IGM-844 + FOLFIRI (+ bevacizumab) (docetaxel included as a part)Phase IUnited States
NCT04256707Selinexor, docetaxel, pembrolizumab, FOLFIRIPhase I/IIIsrael
NCT02817633TSR-022, nivolumab, TSR-042, 033, docetaxel, pemetrexed, cisplatin, carboplatinPhase IUnited States
NCT05714553Fosifloxuridine nafalbenamide, leucovorin, pembrolizumab, docetaxelPhase I/IIUnited Kingdom
NCT04895709BMS-986340, 936558-01, docetaxelPhase I/IIUnited States
NCT04894370(Sample collection)Phase IIFrance
Table 3 The summary of clinical trials investigating CA-4 in cancer treatment
Clinical trial number
Conditions
Trial stage
Enrollment
Study period
NCT01570790Age-related macular degenerationPhase I/II82003-2005
NCT01423149MyopiaPhase II232005-2007
NCT00060242Head and neck cancerPhase II262003-2008
NCT00113438Cancer (non-specified)Phase II232005-2007
NCT00960557Neoplasm metastasisPhase I162009-2010
NCT00077103Head and neck cancerPhase I/II42003-2007 (terminated)
NCT00003768Adult solid tumor (unspecified)Phase I251998-2001
NCT00507429Anaplastic thyroid cancerPhase II/III802007-2011 (terminated)
NCT01023295Polypoidal choroidal vasculopathyPhase II202009-2010
NCT00395434Tumors (unspecified)Phase I202006-2007
NCT02576301Acute myelogenous leukemia/myelodysplastic syndromesPhase I/II1052015-2020 (status unknown)
NCT00003698Adult solid tumor (unspecified)Phase I351998-2003
NCT01085656Acute myelogenous leukemia/myelodysplastic syndromesPhase I182011-2016 (terminated)
NCT02279602Neuroendocrine tumorsPhase II72014-2016
NCT00699517SarcomaPhase III3552008-2013
NCT02132468Neuroendocrine tumorsPhase II182014-2016
NCT01701349Anaplastic thyroid cancerPhase III02015-2017 (withdrawn)
NCT00653939Non-small cell lung cancerPhase II632008-2011
NCT02641639Platinum-resistant ovarian cancerPhase II/III912016-2017 (terminated)
NCT01240590Anaplastic thyroid cancerPhase I/II272011-2016